Trials / Completed
CompletedNCT05686863
Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children
Sedative Effect and Safety of Remiazolam Combined With Low-dose Esketamine in Painless Bidirectional Endoscopy in Children
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 1 Month – 17 Years
- Healthy volunteers
- Not accepted
Summary
To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.
Detailed description
It is planned to observe the painless two-way endoscopic examination of children in Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology from November 2022 to May 2023.To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Remazolam for sedation in children undergoing bidirectional endoscopy |
| DRUG | Esketamine | Esketamine |
| DRUG | Propofol | Propofol |
| DRUG | remifentanil | remifentanil |
Timeline
- Start date
- 2023-01-18
- Primary completion
- 2023-07-07
- Completion
- 2023-07-07
- First posted
- 2023-01-17
- Last updated
- 2023-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05686863. Inclusion in this directory is not an endorsement.